Myst Therapeutics Acquisition by Turnstone Biologics

January 20, 2021Client News

Gunderson Dettmer represented client Myst Therapeutics, a biotechnology company focused on advancing novel T-cell therapies for solid tumors, in its acquisition by Turnstone Biologics.

In the announcement of the transaction, CEO of Turnstone Biologics Sammy Farah said, “The Myst platform builds on validated and durable responses in the field and represents a next-generation approach to TILs that aligns directly with our commitment to exploiting the full potential of innate and adaptive tumor immunity. It further strengthens our internal development expertise and expands our opportunity to deliver transformative medicines to the millions of cancer patients underserved by current treatment options."

The Gunderson deal team was led by Tim Ehrlich and included Colin Chapman, James Hauser, Mark Foster, Keith Scherer, Lily Kim, Michael Deitch, Brittany Nicely, Frances Sevilla-Sacasa and John Maciejewski.